Of mention, genes such as C-X-C Motif Chemokine Ligand 10 (CXCL10) and Serpin Family G Member 1 (SERPING1), regulators of T cells and classical complement pathway, respectively, appear to be upregulated in metastatic melanoma treated with iBRAF/MEK, thus suggesting an immunomodulatory role of these genes which may postulate them as possible therapeutic targets to enhance response to targeted therapy [121]. The gene discussed is SERPING1; the disease is metastatic melanoma.